全球生物相似單株抗體市場規模、佔有率、趨勢和成長分析報告（2026-2034）

預計生物類似單株抗體市場將從 2025 年的 170.1 億美元成長到 2034 年的 1,072.9 億美元，2026 年至 2034 年的複合年成長率為 22.71%。

隨著醫療系統尋求生物製藥療法的替代方案，全球生物相似藥單株抗體市場正經歷強勁成長。生物相似藥與原廠生物製藥具有相當的安全性和有效性，使其成為治療癌症和自體免疫疾病等慢性疾病的理想選擇。多種重磅單株抗體專利的到期進一步加速了市場擴張。

關鍵成長要素包括醫療保健支出增加、有利的法規結構以及對價格合理的治療方法的需求不斷成長。慢性病盛行率上升和患者群不斷擴大，正促使製藥公司投資於生物相似藥的研發。生物製程技術和生產能力的進步也提高了生產效率。

隨著更多生物相似藥在已開發市場和新興市場獲得監管部門核准，未來前景一片光明。日益激烈的競爭有望降低治療成本，並改善患者獲得先進療法的機會。生物技術公司之間持續的研究合作和策略夥伴關係將增強產品管線，並確保生物類似單株抗體市場的永續成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球生物相似單株抗體市場：按類型分類

• 市場分析、洞察與預測
• Adalimumab
• Bevacizumab
• Infliximab
• Rituximab
• 曲妥珠單抗
• 其他

第5章：全球生物相似單株抗體市場：依適應症分類

• 市場分析、洞察與預測
• 腫瘤學
• 自體免疫疾病
• 其他

第6章 全球生物相似單株抗體市場：依最終用戶分類

• 市場分析、洞察與預測
• 醫院
• 癌症治療中心
• 其他

第7章 全球生物相似單株抗體市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Teva Pharmaceutical Industries Limited
  • Coherus BioSciences Inc
  • Shanghai Henlius Biotech Inc
  • Celltrion Healthcare Co. Ltd
  • BIOCAD
  • Pfizer Inc
  • Amgen Inc
  • Biocon
  • Biogen
  • Novartis AG

The Biosimilar Monoclonal Antibody Market size is expected to reach USD 107.29 Billion in 2034 from USD 17.01 Billion (2025) growing at a CAGR of 22.71% during 2026-2034.

The Global Biosimilar Monoclonal Antibody Market is witnessing strong growth as healthcare systems seek cost-effective alternatives to expensive biologic therapies. Biosimilars offer similar safety and efficacy profiles compared to reference biologics, making them attractive options for treating chronic diseases such as cancer and autoimmune disorders. The expiration of patents for several blockbuster monoclonal antibodies has accelerated market expansion.

Key growth drivers include increasing healthcare expenditure, supportive regulatory frameworks, and rising demand for affordable biologic treatments. Growing prevalence of chronic diseases and expanding patient populations are encouraging pharmaceutical companies to invest in biosimilar development. Advances in bioprocessing technologies and manufacturing capabilities are also enhancing production efficiency.

Future prospects appear promising as more biosimilars gain regulatory approvals across developed and emerging markets. Increased competition is expected to reduce treatment costs and improve patient access to advanced therapies. Ongoing research collaborations and strategic partnerships among biotechnology firms will likely strengthen the pipeline, ensuring sustained growth in the biosimilar monoclonal antibody market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Adalimumab
• Bevacizumab
• Infliximab
• Rituximab
• Trastuzumab
• Others

By Indication

• Oncology
• Autoimmune Diseases
• Others

By End User

• Hospitals
• Cancer Treatment Centers
• Others

COMPANIES PROFILED

• Teva Pharmaceutical Industries Limited, Coherus BioSciences Inc, Shanghai Henlius Biotech Inc, Celltrion Healthcare Co Ltd, BIOCAD, Pfizer Inc, Amgen Inc, Biocon, Biogen, Novartis AG
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Adalimumab Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Bevacizumab Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Infliximab Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Rituximab Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Trastuzumab Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Autoimmune Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Cancer Treatment Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Indication
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Indication
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Indication
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Indication
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Indication
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Teva Pharmaceutical Industries Limited
  • 9.2.2 Coherus BioSciences Inc
  • 9.2.3 Shanghai Henlius Biotech Inc
  • 9.2.4 Celltrion Healthcare Co. Ltd
  • 9.2.5 BIOCAD
  • 9.2.6 Pfizer Inc
  • 9.2.7 Amgen Inc
  • 9.2.8 Biocon
  • 9.2.9 Biogen
  • 9.2.10 Novartis AG